Mechanistic rationales for targeting interleukin-17A in spondyloarthritis

Mechanistic rationales for targeting interleukin-17A in spondyloarthritis

The term spondyloarthritis (SpA) is used to describe a group of inflammatory autoimmune diseases, including ankylosing spondylitis and psoriatic arthritis, with common genetic risk factors and clinical features. SpA is clinically distinct from rheumatoid arthritis and typically affects the spine, sacroiliac joints, entheses, and, less commonly, peripheral joints. Although the pathogenesis of Sp...

Interleukin-17A and interleukin-23 in morphea

INTRODUCTION Morphea is a disease included in the group of scleroderma type autoimmune diseases. Interleukin (IL)-17A may play a role at every stage of its pathogenesis. The study aimed at evaluation of IL-17A and IL-23 (as the main cytokine which is supposed to stimulate and maintain synthesis of IL-17) in pathogenesis of morphea. MATERIAL AND METHODS The studies were performed on 41 blood s...

Interleukin 6 blockade in spondyloarthritis.

the role of interleukin-17a (il-17a) in depression

context the aim of this review was to address the recent data regarding the role of il-17a in the pathogenesis of depression and its complications, such as cancer. evidence acquisition this review article summarizes the recent data on the role of il-17a in depression, using the pubmed and google scholar databases. results it has been documented that depression may alter the immune response via ...

Targeting Interleukin-17A – An Orchestrator of Neutrophil Mobilisation in the Lungs

This presentation briefly summarizes the immunology and the pathology of the T cell cytokine interleukin-17A (IL-17A) in the lungs and addresses the potential of IL-17A as a pharmacotherapeutical target. Accumulating experimental and clinical evidence suggests that IL-17A is of importance for coordinating the adaptive and the innate components of pulmonary host defence in mammals. This evidence...